Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 295 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaler Placebo Clear all
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Placebo, Albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
94
States / cities
Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study in Subjects With Asthma

NCT00980200
View directory record Official record
Conditions
Asthma
Interventions
Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

NCT01156844
View directory record Official record
Conditions
Persistent Asthma
Interventions
Indacaterol, Placebo to Indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
21
States / cities
Anniston, Alabama • Cypress, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

NCT01525615
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02584257
View directory record Official record
Conditions
Mild Persistent Asthma
Interventions
methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
Other · Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 13, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265
View directory record Official record
Conditions
Severe Asthma
Interventions
Frevecitinib, Placebo
Drug
Lead sponsor
Kinaset Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Lancaster, California • San Jose, California • Brandon, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

NCT04223843
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium + olodaterol, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Andalusia, Alabama • Jasper, Alabama • Brandon, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002, Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

NCT04656093
View directory record Official record
Conditions
COPD, Diabetes, Hypertension
Interventions
Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

NCT03879837
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler, Placebo pressurized metered dose inhaler
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids

NCT00109668
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone dipropionate (QVAR)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

NCT01712516
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149, QAB149, NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

NCT01056159
View directory record Official record
Conditions
Asthma
Interventions
Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 13, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 13, 2026, 10:10 AM EDT